Skip to main content

Table 2 Clinical response and symptomatic remission outcomes in the short-term study by treatment group (efficacy population, n=414)

From: Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder

 

LDX

Placebo

 

30 mg/d (n=115)

50 mg/d (n=117)

70 mg/d (n=120)

All Doses (n=352)

(n=62)

Clinical response, n (%)

77 (67.0)

83 (70.9)

84 (70.0)

244 (69.3b)

23 (37.1b)

Time to median clinical response, a d (95% CI)

16.0 (15.0, 22.0)

15.0 (15.0, 21.0)

15.0 (13.0, 18.0)

15.0 (15.0, 17.0)

31.0 (29.0, NA)

Symptomatic remission, n (%)

51 (44.3)

47 (40.2)

62 (51.7)

160 (45.5c)

10 (16.1c)

Time to median symptomatic remission, d (95% CI)

31.0 (23.0, 37.0)

NA

29.0 (21.0, 31.0)

31.0 (28.0, 37.0)

 
  1. aRelative to baseline time to median clinical response in the 4-week trial.
  2. bSee Figure 1.
  3. cSee Figure 2.
  4. Abbreviations: d day, CI confidence interval, LDX lisdexamfetamine dimesylate, NA not assessed.
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us